Surrozen SRZN
NASDAQ SRZN
$22.19 -0.35 (-1.55%)
As of: Sep 4, 2026 · 2:28 PM EDT

Surrozen (SRZN) Other Operating Expenses (2020 - 2023)

Surrozen (SRZN) posted quarterly Other Operating Expenses of $40000.0 for Q4 2023, down 97.34% quarter-over-quarter from $1.5 million in Q3 2023.

Analysis

Surrozen (SRZN) Other Operating Expenses (2020 - 2023) Analysis & Trends

Surrozen's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $40000.0 for Q4 2023.

  • In Q4 2023, Other Operating Expenses changed N/A year-over-year to $40000.0; the TTM figure through Sep 2024 stood at $40000.0 (down 98.53% YoY), while the FY2023 annual figure was $2.8 million, changed N/A from the prior year.
  • Other Operating Expenses for Q4 2023 stood at $40000.0, down from $1.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $1.5 million in Q3 2023, with the low at -$39.6 million in Q3 2021.
  • The 3-year median for Other Operating Expenses is $40000.0 (2023), against an average of -$9.4 million.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn -
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn
10 Surrozen 258.80 Mn 258.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 40,000.00
Sep 30, 2023 1.51 Mn
Mar 31, 2023 1.21 Mn
Sep 30, 2021 -39.58 Mn
Dec 31, 2020 -10.40 Mn